Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06773195 · ClinicalTrials.gov registry record · Phase 1
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
A Phase 1 study of Myelofibrosis, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 9
- Study locations
NCT06773195 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 37 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (81% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT06773195, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 9
- Study locations
Study Summary
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participants when given in combination with ruxolitinib.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Ulixertinib
Study Locations (9)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Massachusetts
- Massachusetts General Hospital (Data Collection Only) - Boston
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06773195
The ClinicalTrials.gov registry entry for NCT06773195 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (81% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT06773195 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06773195 about?
NCT06773195 is a clinical study titled "A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis". The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participa...
What is the current status of trial NCT06773195?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-01-07. Estimated completion is 2028-01.
What conditions does trial NCT06773195 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT06773195?
The interventions under investigation include: Ruxolitinib (DRUG), Ulixertinib (DRUG).
Who is sponsoring clinical trial NCT06773195?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06773195 being conducted?
This trial has 9 study locations across Massachusetts, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Jaktinib
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.